The global recombinant DNA technology market is projected to reach a value of USD 1,623.52 billion by 2034, according to a new report by BioSpace. This growth is attributed to the increasing demand for genetically modified organisms, biopharmaceuticals, and advancements in genetic engineering techniques.
Recombinant DNA technology involves combining DNA molecules from different sources to create new genetic sequences. This technology is widely used in a variety of industries, including agriculture, medicine, and biotechnology. In the medical field, recombinant DNA technology is crucial for producing biopharmaceuticals such as insulin, growth hormones, and vaccines.
The market is expected to see significant growth in the coming years due to the rising prevalence of chronic diseases and the development of personalized medicine. Additionally, the increasing adoption of genetically modified organisms in agriculture is driving the demand for recombinant DNA technology.
Key players in the market include Thermo Fisher Scientific, Lonza Group, Merck KGaA, and Agilent Technologies. These companies are investing heavily in research and development to bring innovative products to the market and expand their presence globally.
The report also highlights the challenges facing the recombinant DNA technology market, such as regulatory concerns and ethical issues surrounding genetic engineering. However, with advancements in technology and increasing awareness of the benefits of genetically modified organisms, the market is expected to continue growing at a rapid pace.
Overall, the global recombinant DNA technology market is poised for significant growth in the coming years, driven by the increasing demand for genetically modified organisms and biopharmaceuticals. As companies continue to invest in research and development, the market is expected to reach a value of USD 1,623.52 billion by 2034.
Source
Photo credit news.google.com